RIGEL PHARMACEUTICALS INC 8-K

What Happened

• Rigel Pharmaceuticals (RIGL) filed an 8-K on Feb 3, 2026 reporting that Michael P. Miller was appointed to the company’s board of directors effective Feb 1, 2026. Mr. Miller joins the director class whose term expires at the 2027 annual meeting and will serve on the Compensation Committee.

Key Details

• Appointment effective date: February 1, 2026; filing dated February 3, 2026.
• Cash compensation: annual retainer of $50,000 plus $10,000 annual retainer for service on the Compensation Committee (pro-rated for partial periods).
• Equity awards: initial non-discretionary option to purchase 12,000 shares; thereafter, automatic annual grants of 3,000 option shares and 2,500 restricted stock units following each annual meeting (pro-rated for partial years).
• Governance: Rigel entered its standard indemnification agreement with Mr. Miller; the Board has determined he is independent and there are no family or related-party transactions requiring disclosure.

Why It Matters

• This is a routine board-level change that affects Rigel’s governance and oversight, particularly on the Compensation Committee where Mr. Miller will serve.
• The cash and equity grants are standard non-employee director compensation; while they create modest ongoing compensation expense and potential share dilution over time, the filing does not indicate any extraordinary financial impact.
• Investors watching board composition, independence, and committee membership can view this as a standard governance update reflecting Rigel’s director recruitment and compensation practices.